Navam Capital

Invictus Oncology Pvt. Ltd. is a biopharmaceutical company based in New Delhi, India, established in 2011. The company focuses on developing innovative therapeutics for cancer treatment, aiming to improve the lives of cancer patients. It specializes in supramolecular therapeutics, which are designed to serve as next-generation treatments targeting various cancer types, including lung, testicular, colorectal, and childhood cancers. Invictus Oncology emphasizes the creation of the first anti-cancer drug from India, utilizing advanced technology to design treatments that specifically target tumors and enhance the immune response. This approach enables oncologists to effectively combat cancer cells by activating the patient's immune system.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Invictus Oncology Pvt. Ltd. is a biopharmaceutical company based in New Delhi, India, established in 2011. The company focuses on developing innovative therapeutics for cancer treatment, aiming to improve the lives of cancer patients. It specializes in supramolecular therapeutics, which are designed to serve as next-generation treatments targeting various cancer types, including lung, testicular, colorectal, and childhood cancers. Invictus Oncology emphasizes the creation of the first anti-cancer drug from India, utilizing advanced technology to design treatments that specifically target tumors and enhance the immune response. This approach enables oncologists to effectively combat cancer cells by activating the patient's immune system.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

EnNatura Technology Ventures is a clean materials company based in New Delhi, India, founded in 2006. The company specializes in developing specialty chemicals derived from renewable sources, focusing on designing polymers that aim to reduce hydrocarbon consumption. Additionally, it offers a resin platform tailored for the printing ink industry, along with eco-friendly printing inks, promoting sustainable practices within this sector.